Annual report pursuant to Section 13 and 15(d)

Segment reporting (Details) - Schedule of financial information represents the operating results of the reportable segments

v3.22.2.2
Segment reporting (Details) - Schedule of financial information represents the operating results of the reportable segments - USD ($)
$ in Thousands
 12 Months Ended
Jul. 31, 2022
Jul. 31, 2021
Jul. 31, 2020
Clinical Laboratory Services [Member]      
Segment Reporting Information [Line Items]      
Revenues $ 74,428 $ 86,984 $ 47,964
Grant income     1,496
Total     49,460
Operating costs and expenses:      
Cost of revenues 45,891 48,179 38,855
Research and development 1,329 615 1,509
Selling, general and administrative 26,173 26,028 23,533
Legal and related expenses 254 264 211
Legal settlements    
Total operating costs and expenses 73,647 75,086 64,108
Operating income (loss) 781 11,898 (14,648)
Other income (expense)      
Interest (19) (17) (36)
Other 77 (18) 45
Foreign exchange gain (loss)
Income (loss) before taxes 839 11,863 (14,639)
Depreciation and amortization included above 1,711 1,609 1,553
Share-based compensation included above:      
Selling, general and administrative 190 33 57
Cost of sales 8 93 46
Total 198 126 103
Capital expenditures 929 3,352 1,811
Life Sciences Products [Member]      
Segment Reporting Information [Line Items]      
Revenues 32,643 30,747 26,561
Grant income    
Total     26,561
Operating costs and expenses:      
Cost of revenues 19,213 15,975 13,396
Research and development 2,383 2,559 2,190
Selling, general and administrative 11,604 11,015 10,485
Legal and related expenses 186 25 2
Legal settlements (500)    
Total operating costs and expenses 32,886 29,574 26,073
Operating income (loss) (243) 1,173 488
Other income (expense)      
Interest 45 37 56
Other 4 7 13
Foreign exchange gain (loss) (2,222) 270 905
Income (loss) before taxes (2,416) 1,487 1,462
Depreciation and amortization included above 813 756 964
Share-based compensation included above:      
Selling, general and administrative 22 102 74
Cost of sales 6
Total 28 102 74
Capital expenditures 1,915 752 322
Therapeutics [Member]      
Segment Reporting Information [Line Items]      
Revenues
Grant income    
Total    
Operating costs and expenses:      
Cost of revenues
Research and development 55 78 749
Selling, general and administrative 62
Legal and related expenses
Legal settlements    
Total operating costs and expenses 55 140 749
Operating income (loss) (55) (140) (749)
Other income (expense)      
Interest
Other
Foreign exchange gain (loss)
Income (loss) before taxes (55) (140) (749)
Depreciation and amortization included above
Share-based compensation included above:      
Selling, general and administrative
Cost of sales
Total
Capital expenditures
Other [Member]      
Segment Reporting Information [Line Items]      
Revenues
Grant income    
Total    
Operating costs and expenses:      
Cost of revenues
Research and development
Selling, general and administrative 10,241 7,800 8,942
Legal and related expenses 5,249 4,439 6,516
Legal settlements    
Total operating costs and expenses 15,490 12,239 15,458
Operating income (loss) (15,490) (12,239) (15,458)
Other income (expense)      
Interest 133 (12) 434
Other (1,272) 6,916 430
Foreign exchange gain (loss)
Income (loss) before taxes (16,629) (5,335) (14,594)
Depreciation and amortization included above 303 288 263
Share-based compensation included above:      
Selling, general and administrative 1,270 679 756
Cost of sales
Total 1,270 679 756
Capital expenditures 628 332 37
Consolidated [Member]      
Segment Reporting Information [Line Items]      
Revenues 107,071 117,731 74,525
Grant income     1,496
Total     76,021
Operating costs and expenses:      
Cost of revenues 65,104 64,154 52,251
Research and development 3,767 3,252 4,448
Selling, general and administrative 48,018 44,905 42,960
Legal and related expenses 5,689 4,728 6,729
Legal settlements (500)    
Total operating costs and expenses 122,078 117,039 106,388
Operating income (loss) (15,007) 692 (30,367)
Other income (expense)      
Interest 159 8 454
Other (1,191) 6,905 488
Foreign exchange gain (loss) (2,222) 270 905
Income (loss) before taxes (18,261) 7,875 (28,520)
Depreciation and amortization included above 2,827 2,653 2,780
Share-based compensation included above:      
Selling, general and administrative 1,482 814 887
Cost of sales 14 93 46
Total 1,496 907 933
Capital expenditures $ 3,472 $ 4,436 $ 2,170